Dr. Canetta held numerous roles at Bristol-Myers Squibb (BMS), including head of clinical cancer research; head of development, life cycle management; vice president, oncology global clinical research; and vice president, global R&D oncology policy. His work resulted in the introduction of 18 new BMS drugs for general medical use and the approval of over 50 regulatory dossiers for additional indications/formulations including some outside of oncology.
Prior to his time at BMS, Dr. Canetta conducted clinical trials in lymphomas and gastrointestinal tumors at the Istituto Nazionale Tumori in Milan.
After retiring from BMS in 2015, Dr. Canetta has been consulting for and collaborating with not-for-profit organizations, advocacy groups, government agencies and professional societies.
